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plantation (AlloSCT) from EBV positive HLA matched sibling
or unrelated adult donors.
Methods: EBV positive patients with poor-risk HL will
receive a reduced intensity conditioning regimen followed
by an allogeneic stem cell transplant from EBV positive HLA
matched sibling or unrelated adult donor combined with up
to three doses of post AlloSCT allogeneic donor derived LMP
speciﬁc cytotoxic T-lymphocyte (CTL) infusions (Fig 1A) as
previously described.(Bollard et al, Blood 2007)
Results: To date, our ﬁrst patient has successfully completed
therapy e a 20yr-old male with EBV+ relapsed/refractory
Hodgkin Lymphoma who received his donor EBV-CTL infu-
sion approximately 60 days post AlloSCT from an EBV+ 10/10
MUD donor without adverse effect or complication.
Conclusions: The development of this multicenter LCTC
consists of 9 outstanding multidisciplinary academic centers
(Fig 1B) that comprise expertise in CAYA clinical and trans-
lational lymphoma research, lymphoma biology and bio-
pathology, stem and cell therapy, targeted cell therapy
manufacturing (GMP), biostatistics and bioinformatics, and
expertise in state and federal regulatory compliance. This
consortium is poised to rapidly translate targeted cell ther-
apy in CAYA with high- or poor-risk lymphomas. Further
results from this trial will provide critical information to
develop future randomized trials investigating the use of
donor derived LMP-CTLs.
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Non-Myeloablative Allogeneic Hematopoietic Stem Cell
Transplantation in Hodgkin’s Disease
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (HSCT) is a potential curative treatment forPatients Donor CMV ab,
patient
CMV ab,
donor
MUD MRD Pos Neg Pos Neg
Female n[10 5 5 3 7 5 5
Male n[12 7 5 5 7 6 6relapsed Hodgkin’s Disease. Here we report the results from
a single center institution.
Materials and Methods: A retrospective study was per-
formed with 22 patients with Hodgkin’s Disease who un-
derwent non-myeloablative allogeneic (NMA) HSCT in the
period October 1996 to June 2014 at The Bone Marrow
Transplant Unit, Rigshospitalet, Copenhagen. All patients had
previously received multiple regimens of chemotherapy,
including HDT with autologous stem cell support, 7 patients
had CR at the time of transplantation, others had stable
disease/PR, Ann Arbor stage I-IV. The NMA conditioning
regimens were: Fludarabine 90 mg/m2 and TBI 2 Gy for 19
patients and the 3 patients who received umbilical cord
blood (UCB): Fludarabine 160 mg/m2, Cyclofosfamide
50 mg/kg and TBI 2 Gy. There were 12 males and 10 females,
median age 34.6 years, range 17 to 64.
Results: The overall survival rate was 29.7%, with a median
observation time of 30 months, range 1 to 154 months.
Fourteen of 22 patients developed acute graft versus host
disease grade 1 to 3. Thirteen of 22 died; causes of death
were: toxicity (n¼ 5), relapse/progressive disease (n¼ 6) and
other malignancies (n¼ 2).
Discussion: Despite a theoretical graft versus lymphoma
effect has been discussed in Hodgkin’s Disease, this effect
seems modest in our cohort. More efﬁcient allogeneic
transplant protocols are warranted for relapsed Hodgkin’s
disease.258
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Novel agents and autologous stem cell transplantation
(ASCT) have dramatically prolonged overall survival (OS) of
patients with multiple myeloma (MM). However, almost all
patients relapse within several years after ASCT and some
patients are refractory to standard treatment strategy. Allo-
geneic stem cell transplantation (allo-SCT) is potentially
curative treatment option because of its tumor free graft and
Abstracts / Biol Blood Marrow Transplant 21 (2015) S185eS205S198possibly graft-versus-myeloma effect, but high incidence of
treatment related mortality (TRM) has been reported.
We report consecutive 10 patients with relapsed and re-
fractory MM undergoing allo-SCT in Japanese Red Cross
Medical Center between 2009 and 2014. Median age at
transplantation was 50.5 (31-60). Number of previous ASCT
was one in 5 patients and two in the others. Conditioning
regimen consisted of ﬂudarabine (Flu; 125mg/m2),
melphalan (Mel; 140mg/m2), and total body irradiation
(TBI; 0Gy:1, 2Gy:1, 4Gy: 1, 8Gy:7). Tacrolimus or cyclo-
sporine with or without short term MTX was used as GVHD
prophylaxis. Three out of ten patients received matched
related peripheral blood stem cells and the others received
unrelated stem cells (unrelated bone marrow: 5, cord blood:
2). Two years progression free survival (PFS) and OS were
39.4% and 57.9%, respectively. Interestingly, among patients
transplanted from unrelated donors, two years PFS and OS
were 41.7% and 80%, respectively. In this analysis, three
patients died and causes of death were TRM in one patient
with infection and disease progression in two patients. In
earlier reports, myeloablative regimens were associated
with high early mortality rate, because of acute graft versus
host disease (aGVHD) and infection. In our report, 8 patients
developed grade 2-4 aGVHD (grade 2: 5, grade 3: 3, grade4:
0), but none of them died. Although number of patients is
small, allo-SCT with Flu+Mel+TBI is a tolerable and effective
treatment option for relapsed and refractory MM even with
unrelated donors.259
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Background: Mogamulizumab (anti-CCR4 monoclonal
antibody; MOG) is effective as a treatment for adult T-cell
leukemia/lymphoma (ATLL), but the inﬂuence of MOG
administration before allogeneic hematopoietic cell trans-
plantation (allo-HCT) on transplant outcomes is not clear.
We compared transplant outcomes in patients who
received MOG before allo-HCT with outcomes in those who
did not.
Methods: This study included 88 patients with ATLL who
underwent their ﬁrst allo-HCT between January 2001 and July
2014 at the National Cancer Center Hospital. Three patients
who received cord blood transplantation were excluded.
Results: MOG was used in 11 patients before allo-HCT. The
median time from the last MOG administration to allo-HCT
was 46 days (range, 17-198 days), and the median number
of administration was 5 times (range, 1-8 times). The me-
dian follow-up period among survivors was 1505 days after
HCT (range, 100-4393 days) in all patients, and the MOG
group had a shorter follow-up period (median 249 days,
range 101-284 days). More patients received tacrolimus-
based GVHD prophylaxis in MOG group than in non-MOG
group (n¼10 (91%) vs. n¼42 (55%), P¼0.024). There was no
signiﬁcant difference in other patient- and transplant-
related characteristics. The incidences of grade II-IV and
grade III-IV acute GVHD were 82% and 36%, respectively, inMOG group and 46% and 17%, respectively, in non-MOG
group. The incidence of grade II-IV acute GVHD in MOG
group was signiﬁcantly higher than that in non-MOG group
(P¼0.003). The cumulative incidence rate of non-relapse
mortality (NRM) and the overall survival (OS) rate at 6
months after allo-HCT were 58.2% and 31.8%, respectively, in
MOG group and 13.1% and 76.5%, respectively, in non-MOG
group. Patients in MOG group had signiﬁcantly worse out-
comes than those in non-MOG group (NRM, P¼0.001; OS,
P¼0.006). In MOG group, main causes of NRM included
infection after acute GVHD (n¼3) and multiple organ failure
(n¼2). In multivariate analyses, MOG administration before
HCT was a risk factor for grade II-IV acute GVHD (HR 3.57,
95%CI 1.62-7.78, P¼0.002) and NRM (HR 4.58, 95%CI 1.78-
11.82, P¼0.002).
Conclusion: Despite the small sample size and short obser-
vation period, our data suggested that the administration of
MOG before allo-HCT could increase risks of acute GVHD and
NRM. Appropriate management of acute GVHD including
prophylaxis and treatment should be investigated for ATLL
patients who received MOG before allo-HCT.260
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Hematopoietic stem cell transplantation (HSCT) is an
effective treatment for patients with refractory lymphomas.
Nucleoside analogues (NA) and DNA alkylating agents are
efﬁcacious in treating hematologic malignancies. To design
an efﬁcient, safe and more economical pre-transplant
conditioning regimen for lymphoma patients, we investi-
gated the cytotoxicity of cladribine (Clad), gemcitabine
(Gem), busulfan (Bu) and the histone deacetylase inhibitor
suberoylanilide hydroxamic acid, SAHA, as single agents, or
in combination, in the lymphoma cell lines J45.01 and
U937. [Clad+Gem+Bu] combinations synergistically inhibi-
ted the proliferation of both cell lines to 40-60% relative to
the control. Addition of SAHA to this combination increased
the inhibition to 55-70%. Investigation of the underlying
mechanisms of their synergism indicated that exposure of
lymphoma cells to [Clad+Gem+Bu] combination resulted in
DNA damage, activation of the ATM-CHK2 pathway, histone
modiﬁcations, decrease in the level of anti-apoptotic pro-
teins, and decrease in mitochondrial membrane potential
which caused leakage of apoptosis-inducing factors such
as cytochrome c and Smac/Diablo into the cytosol. These
cytocidal effects were greatly enhanced by SAHA. Pre-
treatment of J45.01 cells with a pan-caspase inhibitor,
Z-VAD-FMK, prior to exposure to the [Clad+Gem+Bu+SAHA]
combination blocked the activation of caspases, which
alleviated DNA damage and apoptosis, as shown by de-
creased phosphorylation of histone 2AX and cleavage of
PARP-1. Exposure of J45.01 cells to SAHA 4 hours prior to
the addition of the [Clad+Gem+Bu] combination resulted in
58% inhibition of proliferation relative to control, while
continuous exposure to [Clad+Gem+Bu] combination alone
